Search clinical trials for: Gleevec/Glivec

Total 3896 results

University of Aarhus

Completed

Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec (NSF)

Nephrogenic Systemic Fibrosis

Denmark
Novartis Pharmaceuticals

Completed

Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumors

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis

Systemic Sclerosis, Scleroderma

United States, Germany, Italy, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia

Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
Novartis Pharmaceuticals

Terminated

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)

Russian Federation
University of Milano Bicocca

Completed

Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV)

Chronic Myeloid Leukemia

Canada, Germany, Israel, Italy, Spain
Novartis Pharmaceuticals

Completed

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

CHRONIC MYELOGENOUS LEUKEMIA

Canada, Australia, Spain, Argentina, France, Brazil
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Glivec Phase II Pediatric Study

Cancer

France, United Kingdom, Netherlands
King Faisal Specialist Hospital & Research Center

Completed

An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Leukemia, Myeloid, Chronic
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene

Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)

United States, Finland, Australia
Novartis Pharmaceuticals

Completed

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib (LASOR)

Chronic Myelogenous Leukemia

China, Argentina, Russian Federation, Germany, Guatemala, Panama, Colombia, Mexico, Brazil, India, Poland, Venezuela
Novartis Pharmaceuticals

Terminated

A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome

Hypereosinophilic Syndrome

Belgium
Novartis Pharmaceuticals

Completed

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

Philadelphia Chromosome Positive CML

United States, Germany, Italy, France
Il-Yang Pharm. Co., Ltd.

Completed

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Bone Marrow Diseases | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Philadelphia Chromosome

Korea, Republic of, Indonesia, Thailand, Philippines
Sarcoma Alliance for Research through Collaboration
Novartis Pharmaceuticals

Terminated

Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

Gastrointestinal Stromal Tumors

United States
Novartis Pharmaceuticals

Completed

A Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)

Gastrointestinal Stromal Tumor (GIST)

China, South Africa, United States, France, Italy, United Kingdom, Germany, Taiwan, Turkey, Canada, Egypt, Singapore, Argentina, Austria, Poland, Russian Federation, Spain, Sweden, Thailand, Korea, Republic of, Bulgaria, Denmark, Japan and more
Novartis Pharmaceuticals

Completed

Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) (INV555)

Gastrointestinal Stromal Tumors

Saudi Arabia, Taiwan, Turkey, Egypt, Thailand, Russian Federation, South Africa, Lebanon, India, Tunisia, Algeria, Jordan
Ariad Pharmaceuticals

Terminated

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Chronic Myeloid Leukemia

United States, Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Hong Kong, Italy, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, Slovakia, Spain, Sweden, Switz... and more
University of California, San Francisco
Juvenile Diabetes Research Foundation

Completed

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDM

United States, Australia
Novartis Pharmaceuticals

Completed

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Leukemia

China
Novartis Pharmaceuticals

Terminated

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) (TOPS)

Leukemia, Myeloid, Chronic Phase

United States, Argentina, Italy, Canada, Australia, Brazil
Bristol-Myers Squibb
PPD; ICON Clinical Research; Q2 Solutions; Molecular MD; MultiPharma; Steering Committee and other collaborators

Completed

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)

Chronic Phase Chronic Myeloid Leukemia

Italy, Thailand, United States, Belgium, Czechia, Hungary, Argentina, Austria, Brazil, Canada, China, France, Korea, Republic of, Poland, Spain
Brigham and Women's Hospital
National Heart, Lung, and Blood Institute (NHLBI); Baim Institute for Clinical...

Completed

Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA) (KIA)

Asthma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Uterine Carcinosarcoma | Recurrent Uterine Sarcoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Acral Lentiginous Malignant Melanoma

United States
National Cancer Institute (NCI)

Completed

A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer

Stage IV Gastric Cancer | Recurrent Gastric Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Bristol-Myers Squibb

Completed

Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (START rollover)

Leukemia

Germany, Italy, Korea, Republic of, Sweden, Thailand, United States, Australia, France, Poland, Switzerland, Spain, Ireland, Peru, Brazil, South Africa, Canada, Argentina, Hungary, Finland, Israel, Norway, Russian Federation, United... and more
National Cancer Institute (NCI)

Completed

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Recurrent Neuroendocrine Carcinoma of the Skin | Stage III Neuroendocrine Carcinoma of the Skin | Stage II Neuroendocrine Carcinoma of the Skin

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

Gastrointestinal Stromal Tumor

United States
Rennes University Hospital
Novartis; Ministry of Health, France

Completed

Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children (ESPHALL)

Acute Lymphoblastic Leukemia | Philadelphia Chromosome

France
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Austria, Germany, United States, United Kingdom
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans

Recurrent Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Dermatofibrosarcoma Protuberans | Adult Fibrosarcoma

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Novartis Pharmaceuticals

Terminated

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENEST)

Myelogenous Leukemia

United States, Germany, Belgium, Italy, Spain, Korea, Republic of, Brazil, Japan, Australia, Czech Republic
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery

Gastrointestinal Stromal Tumor

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

Unspecified Adult Solid Tumor, Protocol Specific | Malignant Neoplasm

United States
University of Liverpool
Imperial College London; Newcastle University; University of Glasgow

Unknown

De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia (DESTINY)

Chronic Myeloid Leukaemia

United Kingdom
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

Recurrent Adult Brain Tumor | Adult Grade I Meningioma | Adult Grade II Meningioma | Adult Meningeal Hemangiopericytoma | Adult Meningioma | Adult Grade III Meningioma

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group; American...

Completed

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

Lung Metastases | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Gastrointestinal Stromal Tumor | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Childhood Synovial Sarcoma | Childhood Desmoplastic Small Round Cell Tumor

United States
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

Testicular Seminoma | Recurrent Ovarian Germ Cell Tumor | Stage II Ovarian Germ Cell Tumor | Stage III Ovarian Germ Cell Tumor | Ovarian Dysgerminoma | Recurrent Malignant Testicular Germ Cell Tumor | Stage II Malignant Testicular Germ Cell Tumor | Stage III Malignant Testicular Germ Cell Tumor

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

Adult Anaplastic Oligodendroglioma | Adult Mixed Glioma | Adult Oligodendroglioma | Recurrent Adult Brain Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Accelerated Phase Chronic Myelogenous Leukemia | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
Emory University

Terminated

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

Leukemia | Chronic Myeloid Leukemia | Chronic Myelogenous Leukemia

United States

Search clinical trials for: Gleevec/Glivec

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations